These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28488248)

  • 21. Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis.
    Reynolds G; Gibbon JR; Pratt AG; Wood MJ; Coady D; Raftery G; Lorenzi AR; Gray A; Filer A; Buckley CD; Haniffa MA; Isaacs JD; Hilkens CM
    Ann Rheum Dis; 2016 May; 75(5):899-907. PubMed ID: 25923217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα.
    Castro-Villegas C; Pérez-Sánchez C; Escudero A; Filipescu I; Verdu M; Ruiz-Limón P; Aguirre MA; Jiménez-Gomez Y; Font P; Rodriguez-Ariza A; Peinado JR; Collantes-Estévez E; González-Conejero R; Martinez C; Barbarroja N; López-Pedrera C
    Arthritis Res Ther; 2015 Mar; 17(1):49. PubMed ID: 25860297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis.
    van Nieuwenhuijze AE; van de Loo FA; Walgreen B; Bennink M; Helsen M; van den Bersselaar L; Wicks IP; van den Berg WB; Koenders MI
    Arthritis Res Ther; 2015 Jun; 17(1):163. PubMed ID: 26081345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis.
    Baldwin HM; Ito-Ihara T; Isaacs JD; Hilkens CM
    Ann Rheum Dis; 2010 Jun; 69(6):1200-7. PubMed ID: 19773288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism.
    Municio C; Dominguez-Soto Á; Fuentelsaz-Romero S; Lamana A; Montes N; Cuevas VD; Campos RG; Pablos JL; González-Álvaro I; Puig-Kröger A
    Ann Rheum Dis; 2018 May; 77(5):752-759. PubMed ID: 29431121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TNFα inhibitors reduce bone loss in rheumatoid arthritis independent of clinical response by reducing osteoclast precursors and IL-20.
    Al-Bogami M; Bystrom J; Clanchy F; Taher TE; Mangat P; Williams RO; Jawad AS; Mageed RA
    Rheumatology (Oxford); 2021 Feb; 60(2):947-957. PubMed ID: 32984900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis.
    Kondo N; Kuroda T; Kobayashi D
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crosstalk between tumor necrosis factor-alpha signaling and aryl hydrocarbon receptor signaling in nuclear factor -kappa B activation: A possible molecular mechanism underlying the reduced efficacy of TNF-inhibitors in rheumatoid arthritis by smoking.
    Nii T; Kuzuya K; Kabata D; Matsui T; Murata A; Ohya T; Matsuoka H; Shimizu T; Oguro E; Okita Y; Udagawa C; Yoshimura M; Kudo-Tanaka E; Teshigawara S; Harada Y; Yoshida Y; Isoda K; Tsuji SI; Ohshima S; Hashimoto J; Shintani A; Takehana Y; Tohma S; Saeki Y
    J Autoimmun; 2019 Mar; 98():95-102. PubMed ID: 30591403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects.
    Crotti C; Agape E; Becciolini A; Biggioggero M; Favalli EG
    Drugs; 2019 Nov; 79(16):1741-1755. PubMed ID: 31486005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis.
    Chara L; Sánchez-Atrio A; Pérez A; Cuende E; Albarrán F; Turrión A; Chevarria J; Sánchez MA; Monserrat J; de la Hera A; Prieto A; Sanz I; Diaz D; Alvarez-Mon M
    Arthritis Res Ther; 2012 Jul; 14(4):R175. PubMed ID: 22838733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature.
    Ingegnoli F; Favalli EG; Meroni PL
    Autoimmun Rev; 2011 Jun; 10(8):460-3. PubMed ID: 21296193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.
    Osiri M; Wongpiyabovorn J; Sattayasomboon Y; Thammacharoenrach N
    Clin Rheumatol; 2016 Jul; 35(7):1673-81. PubMed ID: 27188857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting GM-CSF in rheumatoid arthritis.
    Avci AB; Feist E; Burmester GR
    Clin Exp Rheumatol; 2016; 34(4 Suppl 98):39-44. PubMed ID: 27586802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinctive effects of G-CSF, GM-CSF and TNFalpha on neutrophil apoptosis in systemic lupus erythematosus.
    Armstrong DJ; Whitehead EM; Crockard AD; Bell AL
    Clin Exp Rheumatol; 2005; 23(2):152-8. PubMed ID: 15895883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1β signaling and a poor clinical response.
    Matsuyama Y; Okazaki H; Hoshino M; Onishi S; Kamata Y; Nagatani K; Nagashima T; Iwamoto M; Yoshio T; Ohto-Ozaki H; Tamemoto H; Komine M; Sekiya H; Tominaga S; Minota S
    Rheumatol Int; 2012 May; 32(5):1397-401. PubMed ID: 21431944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody.
    Fischer JA; Hueber AJ; Wilson S; Galm M; Baum W; Kitson C; Auer J; Lorenz SH; Moelleken J; Bader M; Tissot AC; Tan SL; Seeber S; Schett G
    Arthritis Rheumatol; 2015 Jan; 67(1):51-62. PubMed ID: 25303306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis.
    van Hamburg JP; Tas SW
    J Autoimmun; 2018 Feb; 87():69-81. PubMed ID: 29254845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profiling of B-Cell Factors and Their Decoy Receptors in Rheumatoid Arthritis: Association With Clinical Features and Treatment Outcomes.
    Rodríguez-Carrio J; Alperi-López M; López P; Ballina-García FJ; Suárez A
    Front Immunol; 2018; 9():2351. PubMed ID: 30369929
    [No Abstract]   [Full Text] [Related]  

  • 39. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha.
    Alvaro-Gracia JM; Zvaifler NJ; Brown CB; Kaushansky K; Firestein GS
    J Immunol; 1991 May; 146(10):3365-71. PubMed ID: 2026869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors.
    Golinski ML; Vandhuick T; Derambure C; Fréret M; Lecuyer M; Guillou C; Hiron M; Boyer O; Le Loët X; Vittecoq O; Lequerré T
    Arthritis Res Ther; 2015 Dec; 17():382. PubMed ID: 26714738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.